Literature DB >> 12111701

Insulin-like growth factors and risk of benign prostatic hyperplasia.

Anand P Chokkalingam1, Yu-Tang Gao, Jie Deng, Frank Z Stanczyk, Isabell A Sesterhenn, F K Mostofi, Joseph F Fraumeni, Ann W Hsing.   

Abstract

BACKGROUND: Insulin-like growth factors (IGFs) have potent growth mitogenic and anti-apoptotic effects on prostate tissue, whereas IGF binding proteins (IGFBPs) inhibit growth of prostatic tissue. The IGF axis has been implicated in prostate cancer risk, but its role in benign prostatic hyperplasia (BPH) is unclear.
METHODS: Plasma levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3 were determined from the fasting bloods of 206 BPH cases admitted for treatment and 306 randomly selected population controls in Shanghai, China.
RESULTS: Relative to the lowest tertile, men in the highest tertile of IGF-I levels had a significantly elevated risk of BPH (odds ratio [OR] = 2.80, 95% confidence interval [95% CI] = 1.60-4.92; P(trend) < 0.001). Results for IGF-I were more pronounced after adjustment for serum androgens. In contrast, men in the highest IGFBP-3 tertile had a significantly reduced risk (OR = 0.40; 95% CI = 0.23-0.69; P(trend) < 0.001). No associations of BPH with IGF-II and IGFBP-1 were observed.
CONCLUSION: As has been previously observed for prostate cancer, we found that IGF-I and IGFBP-3 are associated with BPH risk in China. Further investigation is needed to elucidate the role of the IGF axis in BPH etiology. Published 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12111701     DOI: 10.1002/pros.10096

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  23 in total

1.  Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia.

Authors:  Ajit Vikram; Gopabandhu Jena; Poduri Ramarao
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

Review 2.  Benign prostatic hyperplasia: dietary and metabolic risk factors.

Authors:  H Nandeesha
Journal:  Int Urol Nephrol       Date:  2008-02-02       Impact factor: 2.370

Review 3.  Risk factors for benign prostatic hyperplasia.

Authors:  Steven J Jacobsen
Journal:  Curr Urol Rep       Date:  2007-07       Impact factor: 3.092

4.  Androgen regulated genes in human prostate xenografts in mice: relation to BPH and prostate cancer.

Authors:  Harold D Love; S Erin Booton; Braden E Boone; Joan P Breyer; Tatsuki Koyama; Monica P Revelo; Scott B Shappell; Jeffrey R Smith; Simon W Hayward
Journal:  PLoS One       Date:  2009-12-21       Impact factor: 3.240

5.  Apigenin Modulates Insulin-like Growth Factor Axis: Implications for Prevention and Therapy of Prostate Cancer.

Authors:  Melissa A Babcook; Sanjay Gupta
Journal:  Curr Drug Targets       Date:  2012-11-06       Impact factor: 3.465

Review 6.  PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.

Authors:  Ming Jiang; Douglas W Strand; Omar E Franco; Peter E Clark; Simon W Hayward
Journal:  Differentiation       Date:  2011-06-08       Impact factor: 3.880

7.  Dietary, but not supplemental, intakes of carotenoids and vitamin C are associated with decreased odds of lower urinary tract symptoms in men.

Authors:  Nancy N Maserejian; Edward L Giovannucci; Kevin T McVary; John B McKinlay
Journal:  J Nutr       Date:  2010-12-22       Impact factor: 4.798

Review 8.  Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol).

Authors:  M Maggi; C Crescioli; A Morelli; E Colli; L Adorini
Journal:  J Endocrinol Invest       Date:  2006 Jul-Aug       Impact factor: 4.256

Review 9.  Diabetes and benign prostatic hyperplasia: emerging clinical connections.

Authors:  Aruna V Sarma; J Kellogg Parsons
Journal:  Curr Urol Rep       Date:  2009-07       Impact factor: 3.092

10.  Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial.

Authors:  Marian L Neuhouser; Jeannette Schenk; Yoon Ju Song; Catherine M Tangen; Phyllis J Goodman; Michael Pollak; David F Penson; Ian M Thompson; Alan R Kristal
Journal:  Prostate       Date:  2008-09-15       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.